Patient cases

Speaker: Jesper Palshof
Date: June 2024
Tags: Patient cases

How to optimize Cabozantinib

Speaker: Niels Fristrup
Date: 24 November 2024
Tags: Treatment timing, optimization and patient stratification

Optimal treatment for patients in favorable IMDC risk group

Speaker: Daniel Heinrich and Katriina Jalkanen
Date: 1st December 2023
Tags: Nordic RCC Summit 2023,Ā First line systemic therapy

Non-drug options in oligometastatic RCC

Speaker: Panu Jaakkola
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape

Approaches to treatment of oligoprogressive disease, Patient case and discussion

Speaker: Jesper Andreas Palshof
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape

nccRCC – Should we change our practice?

Speaker: Katarina Puco
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape

Management of specific drug toxicities: The Immunotoxicity Clinic

Speaker: Jesper Andreas Palshof
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, AE management

Cytoreductive nephrectomy in advanced RCC – Praxis in Sweden

Speaker: Fabian Hofmann
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery

Cytoreductive nephrectomy in advanced RCC – Praxis in Norway

Speaker: Karin Margrete Hjelle
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery

To cut or not to cut: The role of cytoreductive nephrectomy in advanced RCC

Speaker: Arnaud Mejean
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery

Cytoreductive Nephrectomy in advanced RCC – Praxis in Denmark

Speaker: Anna Krarup Keller
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Surgery

Adjuvant treatment in RCC – Status in the Nordics – Sweden

Speaker: Magnus Lindskog
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment

Adjuvant treatment in RCC – Status in the Nordics – Norway

Speaker: Katarina Puco
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment

Adjuvant treatment in RCC – Status in the Nordics – Denmark

Speaker: Niels Fristrup
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment

Adjuvant treatment in RCC

Speaker: Axel Bex
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Adjuvant Treatment

Njurcancer: De vanligaste och kliniskt viktigaste typerna och deras sardrag med fokus pa behandling och prognos

Speaker: Dr Martin Johansson (Swedish only)
Date: 21 September 2023
Tags: Pathology

Kostbehandling vid diarre under onkologisk behandling

Speaker: Leg dietist Maria Berglund, leg dietist Klinisk Nutrition, Akademiska Sjukhuset (Swedish only)
Date: 21 September 2023
Tags: AE management

1st line therapy for metastatic renal cell carcinoma

Speaker: Prof. Dr. Jonas Busch, Department of Urology, Berlin Vivantes Klinikum Am Urban & Im Friedrichshain
Date: 25 May 2023
Tags: Treatment landscape

IO/IO vs IO/TKI in frontline setting mRCC – Pros and Cons

Speaker: Daniel Heinrich Senior Consultant Clinical Oncologist Department of Radiotherapy and Oncology Innlandet Hospital Trust, Norway
Date: 10 May 2023
Tags: Treatment landscape

QoL in mRCC clinical trials

Speaker: Interview with Professor David Cella.
Date: 10 November 2022
Tags: Quality of Life

Case experiences with combination therapy with cabozantinib + nivolumab as first-line treatment

Speaker: Interview with Professor Viktor Grünwald.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Long-Term effectiveness results of CheckMate-9ER

Speaker: Interview with Professor Toni K. Choueiri.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Timing of the treatment and patient stratification

Speaker: Interview with Professor Daniel Heng.
Date: 2 August 2022
Tags: Treatment timing and patient stratification

First-line combination treatments available for renal cell carcinoma

Speaker: Interview with Professor Sumanta Kumar Pal.
Date: 2 August 2022
Tags: Treatment landscape, First line systemic therapy

Quality of life and Patient-Reported Outcome Measures

Speaker: Interview with Professor David Cella.
Date: 2 August 2022
Tags: Quality of Life

Nivolumab + Cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1L

IPSEN and Bristol Myers Squibb webinar.
Speaker
: Petri Bono, Viktor Grünwald, MD and Thomas Powles MBBS, MRCP, MD.
Date: 12 October 2021
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Rationale for combinations with CPI

Speaker: Katarina Puco, Senior Consultant Oncologist. Lovisenberg Diaconal Hospital Norway.
Date: 9 September 2021
Tags: Treatment landscape, First line systemic therapy

How can we help the patient to stay on treatment

Manuela Schmidinger. Medical University of Vienna, Austria.
Date: 29 April 2021
Tags: AE management

What is Renal Cell Carcinoma

By Martin Johansson, Professor in Pathology Sahlgrenska University Hospital/ Gothenburg university
Date: 31 March 2021
Tags: Pathology